Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy-Reference-Cited by-同舟云学术

Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy

Published:2022-11-28 Issue:3 Volume:30 Page:745-748
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Euro J of Neurology

Author:

Chitimus Diana Maria¹,Berling Edouard¹²³^ORCID,Garderet Laurent⁴,Venturelli Nadia⁵⁶,Malfatti Edoardo²⁷⁸,Authier François Jérôme²⁷⁸,Nicolas Guillaume¹²³,Laforêt Pascal¹²³,Lefeuvre Claire¹²

Affiliation:

1. Neurology Department Raymond Poincaré University Hospital, APHP Garches France

2. Nord‐Est‐Ile‐de‐France Neuromuscular Reference Center FHU PHENIX Garches France

3. U 1179 INSERM Université Paris‐Saclay Montigny‐le‐Bretonneux France

4. Haematology Department Hôpital Pitié‐Salpêtrière, APHP Paris France

5. Diagnostic and Interventional Medical Imaging Department Raymond Poincaré Hospital Garches France

6. DMU Smart Imaging GH Université Paris‐Saclay, APHP Garches France

7. U955 INSERM, EnvA, EFS, IMRB Université Paris Est Créteil France

8. Centre de Référence de Pathologie Neuromusculaire Nord‐Est‐Ile‐de‐France, APHP Henri Mondor Hospital Créteil France

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.15640

Reference15 articles.

1. Systemic immunoglobulin light chain amyloidosis

2. Neuromuscular amyloidosis: Unmasking the master of disguise

3. Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in Japan

4. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis

5. Systemic Immunoglobulin Light Chain Amyloidosis–Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome